Mologen AG

Mologen AG, a biotechnology company, develops immunotherapies for the treatment of oncology and infectious diseases. The company’s lead product is Lefitolimod, an immunotherapeutic agent, which is in Phase III study for the treatment of colorectal cancer; Phase II trial for the treatment of small lung cancer; and Phase Ib/IIa study of lefitolimod in human immunodeficiency virus-infected patients under antiretroviral therapy through collaborations with the Aarhus University Hospital in Denmark. Its lead product Lefitolimod is also under Phase I combination study with the checkpoint inhibitor Yervoy to treat advanced solid tumors in collaboration with MD Anderson Cancer Center at the University of Texas, the United States. In addition, the company is involved in the development of EnanDIM molecules, which are under pre-clinical development for cancer/anti-infective therapies; and MGN1601, a cell based therapeutic vaccine, which is has completed Phase I/II trial for the treatment of renal cancer. Mologen AG was founded in 1998 and is headquartered in Berlin, Germany.